Ruiqi Li

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Acute Myeloid Leukemia

Cell Cycle Arrest

Endoplasmic Reticulum Stress

Top Venues

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Fangliang Zhang, Jianai Sun, Lei Zhang, Ruiqi Li, Yanzhen Wang, Huichao Geng, Chao Shen, Ling Li, Liang Chen
PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. British journal of cancer 131 (2) (2024)
Fangliang Zhang, Jianai Sun, Lei Zhang, Ruiqi Li, Yanzhen Wang, Huichao Geng, Chao Shen, Ling Li, Liang Chen
PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. British journal of cancer 131 (2) (2024)
Fangliang Zhang, Jianai Sun, Lei Zhang, Ruiqi Li, Yanzhen Wang, Huichao Geng, Chao Shen, Ling Li, Liang Chen
PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. British journal of cancer (2024)
Fangliang Zhang, Jianai Sun, Lei Zhang, Ruiqi Li, Yanzhen Wang, Huichao Geng, Chao Shen, Ling Li, Liang Chen
PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. British journal of cancer 131 (2) (2024)
Fangliang Zhang, Jianai Sun, Lei Zhang, Ruiqi Li, Yanzhen Wang, Huichao Geng, Chao Shen, Ling Li, Liang Chen
PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. British journal of cancer 131 (2) (2024)
Fangliang Zhang, Jianai Sun, Lei Zhang, Ruiqi Li, Yanzhen Wang, Huichao Geng, Chao Shen, Ling Li, Liang Chen
PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. British journal of cancer 131 (2) (2024)